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Human pharmacokinetics of ceftazidime in comparison to
moxalactam and cefotaxime—abstract
Ruedi Luthy, Jurg Blaser, Antonio BonettL Hanspeter Simmen,
Richard Wise* and Walter Siegenthaler
Department of Medicine, University of Zurich, CH-8091 Zurich,
Switzerland and Department of Medical Microbiology, Dudley
Road Hospital, Birmingham, England*
The present study (Luthy et al., 1981) was conducted to compare the pharmacokinetics
of three different doses of cefotaxime (CTAX), moxalactam (MOXA) and ceftazidime
(CTAZ) and to evaluate the influence of probenecid on the phannacokinetic behaviour
of these three compounds. Six male volunteers received in a cross-over fashion doses of
0-5, 10 and 20 g of each drug by a 5-min infusion. Doses of 10g were repeated after
administration of probenecid. During each study 17 blood samples were drawn to
document the distribution and elimination phases. The urinary excretion was
determined from five quantitative urine collections which were made over the 24 h of the
study. Serum and urine concentrations were assayed by an agar diffusion method, the
assay strain for CTAX being resistant to its desacetyl metabolite. The coefficient of
variation for interassay precision averaged 4-6 ±0-9%. Serum samples of the 05 and
20g doses of CTAX and MOXA were also analysed by a high pressure liquid
chromatography method which provided information on the behaviour of the desacetyl
metabolite of CTAX and the two naturally occurring epimers of MOXA. The
phannacokinetic parameters of a two-compartment open model were adapted to the
experimental data with a non-linear fitting program. For all statistical evaluations the
Wilcoxon matched pairs signed rank test was used. Probabilities 2a^005 were
considered significant.
The 10 min, 6, 8 and 12 h mean serum concentrations of CTAX, MOXA and CTAZ
are presented in Table I. Serum concentrations of MOXA exceeded those of CTAZ at
all times and were distinctly higher than those of CTAX. To facilitate the comparison
between the various doses and drugs, the areas under the serum concentration time
curves (AUC) were normalized by dividing through the individual doses. Compared
with CTAX the normalized AUC of MOXA was three to four times, and of CTAZ two
to three times, higher. Linear regression analysis of the dose (x in [g]) versus normalized
AUC {y in [mg/h//l]) yielded a slope for CTAXCK=13-4X+4512) which was significantly
different from zero (P < 0.001) indicating a non-linear increment in AUC for increasing
doses. In contrast, slopes of MOXA (y=-19-36*+24009) and CTAZ
(y= — 14-59x+168-51) did not differ significantly from zero. The phannacokinetic
parameters of CTAX, MOXA and CTAZ are summarized in Table II. Significant
differences between the three compounds in the total volume of distribution were
observed for the 0-5g dose, but not for the 10 and 20g dose. Intraindividual
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comparisons of the elimination half lives, total body and renal clearances demonstrated
significant differences between these antibiotics. The half-lives calculated from the 0-5,
10 and 20g doses averaged 2-34, 1-95 and 1-16h for MOXA, CTAZ and CTAX,
respectively. The 24 h urinary recovery was highest for MOXA (75 ±4%), followed by
CTAZ (68 ±11%) and CTAX (53 ±6%). Total body and renal clearance of CTAX
decreased significantly with increasing doses. In contrast to MOXA and CTAZ, the
ratio of renal to creatinine clearance indicated that considerable tubular secretion of
CTAX occurred.
The influence of probenecid on serum concentrations, half-life, AUC, volume of
distribution and clearance was most obvious with CTAX. Saturation of tubular
secretion led to serum concentrations with the 10g dose of CTAX which already at 2h
were higher than those achieved with the 20 g dose. The renal clearance of this drug was
decreased by almost 50% and the AUC doubled when probenecid was administered.
This is in contrast to MOXA and CTAZ where the marginal influence of this agent is of
no practical significance.
The desacetyl metabolite of CTAX, determined by high pressure liquid
chromatography, reached its peak 45 min after administration. It averaged 2-7 + 1 0 and
9-8 ± l-8mg/l for the 0-5 and 20 g dose, respectively. Compared to CTAX, its half-life
was approximately twice as long (l-9±0-7h and l-4±0-4h). Following the 0-5g dose
the AUC for the desacetyl metabolite was 31 ± 12% of the total area of CTAX, whereas
for the 20g dose this proportion decreased to 18±2%, suggesting that desacetylation
may not follow first-order kinetics.
Freshly prepared solutions of MOXA contain two epimers, designated R (—) and S
( —), in approximately equal amounts. The serum protein binding of the R (—) epimer
averages 53%, that of the S ( - ) epimer 67% (Yamada et al., 1981). The antimicrobial
Table I. Mean serum concentrations (mg/I) of cefotaxime (CTAX), moxalactam (MOXA) and
ceftazidime (CTAZ) in six volunteers
Drug/dose
level (g)
CTAX/0-5
MOXA/0-5
CTAZ/0-5
CTAX/10
MOXA/1-0
CTAZ/10
CTAX/20
MOXA/20
CTAZ/20
CTAX/10+Pt
MOXA/10 + P
CTAZ/10 + P
Actual
dose(g)*
0-58
0-47
0-48
1-06
0-99
0-96
202
1 87
1-94
0-96
110
0-97
017
37-8±7.1f
63-3 ± 6 0
49-9 ± 8 0
80-8+14-1
120±12-4
107+180
174 ±36-7
210 + 30-8
181 ±23-2
109± 12-3
111 ±10-8
98-9±12-5
Time
6
0-3 ± 0 1 (TI = 3 )
<0-l (*=3)
4-2 ±1-7
21+0-5
0-4 ± 0 1
8-2 ±2-0
4-4±l-4
0-9 ±0-5
14-2 + 2-4
6-6 ±1-5
1-4 ±0-7
10-0+1-7
4-2 ±0-6
(h)
8
<01
2-2 ±0-6
10 ±0-3
<0-l
4-7+10
21 ±0-7
0-5 ±0-4(TJ = 3)
80±l-8
3-8 + 0-9
0-6 ±0-4 (TI = 5)
6-2+1-2
21 ±0-5
12
<01
0-7+0-2
0-3±0-l
<0-l
1-4 ±0-5
0-5 ±0-3
<01
2-6 ±0-8
1-1 ±0-5
<01
2-7 + 0-8
0-5 ±0-2
*Mean value of six administered doses
t ± S. D.
JProbenecid (0-5 g every 6 h on day before study and 1-Og 30 min pre dose).
Table II. Synopsis of pharmacokinetic parameters of cefotaxime (CTAX), moxalactam (MOXA) and ceftazidime (CTAZ). Mean values ± S.D. of six
volunteers
Dose
(g)
CTAX 0-5
10
2 0
10 + P1
MOXA 0-5
01
20
1-0 + P1
CTAZ 0-5
10
2 0
1-0 + P1
vx
d/kg)
0-17 + 004
0-14 + 003
015 ±002
010±001
009 + 001
010 + 001
0-12 + 0-02
013 + 002
014±001
013 + 002
014 + 001
0-13 + 0-01
(I/kg)
0-29 + 005
0-24 + 0-04
0-21 ±004
0-18 + 002
018 + 001
019 + 001
0-23 + 003
0-24 + 002
0-22 + 002
0-21+0-02
0-25 ±002
0-21 ±001
kl2(x lO ' l r 1 )
2-30+1-10
210 + 0-72
100 + 0-43
3-40 + 0-82
2-45 + 0-60
3-35+1-18
2-33 + 0-97
2-38 + 0-67
1-05 + 0-18
1-48+0-53
1-78+0-65
1-32 ±0-20
k2l(x lO ' l r 1 )
3-05+1-12
2-98 + 0-85
2-13+0-73
3-97 + 0-55
2-63 + 0-73
3-47+1-03
2-48 + 0-47
2-53 + 0-47
1-97 + 0-33
2-18 + 0-33
2-37 + 0-65
2-23+0-35
(h)
110 + 0-38
1-08 + 0-27
1-31+0-32
115 + 003
2-35 + 0-32
2-25 + 0-21
2-42 + 013
2-79 + 0-24
201+016
1-87 + 015
1-96 + 0-18
l-97±0-17
cb(ml/min)
391+97
326 + 48
267+49
169+16
77-8 + 9-4
81-2±10-6
94-4+15-7
83-2 + 9-6
144+16
116+18
133 + 20
114+13
feU
(%)
58 + 12
47 + 7-9
56+18
51+3-6
79 + 4-8
71+7-3
73 + 5-2
67 + 6-9
66 + 2-8
75 + 3-3
60 + 9-1
68+4-2
cr(ml/min)
217 + 31
154 + 38
145 + 48
85 + 8-8
61-7 + 9-0
580 ±9-2
69-4+14-6
55-7+11-6
75-1 + 11-6
87-6+161
81-1 + 17-6
78-6 + 9-4
(ml/min)
129+18
132+16
141 + 18
124+10
135+18
140± 17
141 + 10
130+16
131+24
143 + 24
121 + 12
133 + 44
cjccr
1-69 + 0-11
116 + 0-22
1-03+0-29
0-69 + 0-10
0-46 + 006
0-41+0-05
0-49 + 0-08
0-43 + 010
0-58 + 0-09
0-61+005
0-67+0-12
0-64 + 0-19
Parameters for CTAX were derived from a two-compartment model fitted to serum data of the first 6h only, whereas for MOXA and CTAZ all
measured data were included.
Vt volume of distribution of the central compartment; Vd total volume of distribution; k12, k2l rate constants of transfer between the two
compartments; 7$ terminal half life; Cb total body clearance; feU excreted urinary fraction of the administered dose; Cr renal clearance; Ccr creatinine
clearance.
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activity of the former is approximately doubled compared to S ( — ) (R. Wise et al.,
1981). Analysis of the two epimers revealed that their pharmacokinetic behaviour is
different. Ten minutes following the intravenous administration the ratio of the R ( — )
to the S ( — ) epimer was 0-84 and fell rapidly to 0-5 at 5 h, indicating the presence of
twice as much of the S ( — ) epimer compared to R ( — ). At this time the antimicrobial
activity determined by the agar diffusion assay is reduced by one-fourth when compared
to HPLC analysis.
No side effects were recorded throughout the entire study and chemistry profiles,
blood counts, urinalysis and creatinine clearance remained within normal limits.
This study demonstrated that significant differences exist between the
pharmacokinetic behaviour of CTAX, MOXA and CTAZ. From this standpoint it
appears reasonable to conclude that MOXA and possibly CTAZ could be administered
twice daily and CTAX three or even four times daily.
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